




# 11th Annual CAR-TCR Summit

## Engineering a Disease-Free World

September 15-17, 2026 | Boston, MA

Advancing the Development of Targeted, Scalable Cell Therapies through Disruptive *Ex Vivo* & *In Vivo* Technologies, Automated Manufacturing & Strategic Partnerships to Safeguard the Commercial Success of the Industry

75+ World-Class Speakers, Including:



**Bill Querbes**  
Chief Scientific Officer  
Aera Therapeutics



**Nikhil Mutyal**  
Global Head of Search & Evaluation, Respiratory & Immunology  
AstraZeneca



**Ruth Salmon**  
Vice President,  
Preclinical Sciences  
Bristol Myers Squibb



**Adrian Kilcoyne**  
Chief Medical Officer  
Cellectis



**Pei Wang**  
Senior Vice President,  
Clinical Development  
Eureka Therapeutics



**Chris Crowell**  
Global Head,  
Manufacturing  
Kite Pharma



**Helen Sabzevari**  
President & Chief  
Executive Officer  
Precigen



**Natalie Shiff**  
Senior Medical Director  
Fate Therapeutics



SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

### CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION

Lead Partner:



Expertise Partners:

SARTORIUS

Lonza

[www.car-tcr-summit.com](http://www.car-tcr-summit.com) Tel: +1 617 455 4188 Email: [info@hansonwade.com](mailto:info@hansonwade.com) [in](#) CAR-TCR Summit Series



REGISTER  
NOW

# Welcome to the Heart of Cell Therapy Progress at the 11th CAR-TCR Summit

In 2026, the CAR-T conversation is shifting from **early momentum to long-term sustainability**. The focus is now on proving clinical success across solid tumors, haematological malignancies, and autoimmune diseases, while driving down COGs and unlocking broader patient access.

With **\$6.6 billion invested in *in vivo* CAR-T in 2025**, the signal is clear: capital is flowing back into the space, but only where next-generation approaches can deliver on cost efficiency, scalability, and real-world competitiveness.

Against this backdrop, the **11th CAR-TCR Summit** returns as the **leading, deeply technical, flagship cell therapy forum**. Uniting top scientific and strategic decision makers all with one goal: to drive the innovation and commercial readiness needed to make CAR-T therapies safer, more effective, scalable, and accessible to the patients who need them most.

As your must attend cell therapy forum in 2026, don't miss **unpublished clinical data from Phase I and II trials**, insights from pioneering **CAR-T academic leaders**, and forward-looking perspectives from **venture capital** to hear first hand how to secure funding and extend your cash runway. Collectively, these conversations are designed to accelerate the development of targeted, scalable cell therapies through disruptive ***ex vivo*** and ***in vivo* technologies**, **automated manufacturing** and **strategic commercial partnerships** to safeguard the success of the industry.

With 4 dedicated tracks on **Discovery & Translation**, **Clinical**, **Early-Stage Manufacturing** and **Late-Stage Manufacturing**, the summit integrates science, development and business strategy within a single forum. Divide and conquer with your cross-functional team to:


- Discover novel modalities and biomarkers for complex solid tumor and autoimmune indications with AI and translational relevance
- Accelerate clinical impact with **smarter trial design**, **clinical readouts** across dual CAR-T, TCR-T and allogeneic approaches and patient-centric strategies
- Build early-stage Phase I processes with **speed, flexibility and a clear path to commercialization**
- Tailor late-stage manufacturing strategies to **effectively scale up, reduce costs and ensure quality** in Phase II and beyond

Built to deliver tailored, data-led insights across the full cell therapy landscape, this is your definitive event to connect with the leaders shaping the future of the industry. Collaborate with C-suite and senior decision-makers, cross-functional experts, academic KOLs and patient voices, offering you an unrivaled platform to benchmark strategy, challenge convention, and accelerate the delivery of life-saving therapies to patients in need.

We hope you can join us!

The CAR-TCR Team

## 11th CAR-TCR Summit in Numbers:



## Your Scientific Advisory Board:

We're proud to unveil your 2026 Scientific Advisory Board. This exceptional team has supported in shaping the foundation of the event. Bringing bold insight into key challenges, breakthrough data and game-changing innovations, they've helped to ensure every moment is focused, impactful and truly unmissable.



**Sidharth Kerkar**  
Founder & Chief Executive Officer  
**Allergene AI**



**Koji Yasuda**  
Principal  
**Fast Track Initiative**



**Vicki Plaks**  
Senior Director, Scientific Head of Cell Therapy Oncology, Translational Research  
**Johnson & Johnson**

“The CAR-TCR Summit is the key event of the year to meet all relevant industry and academic stakeholders in the field of T-cell therapies against cancer and autoimmune diseases.”

Felix Lorenz, Chief Executive Officer & Chief Scientific Officer, **Captain T Cell**, 2026 Speaker

SAVE \$1,000 BY REGISTERING BEFORE FRIDAY, MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS


PRICING & REGISTRATION



REGISTER NOW

# What's New: 360° Perspectives Across Data, Patients & Commercialization

As the industry works to unlock life-changing therapeutic potential and secure critical clinical validation, innovations across diverse cell types are emerging rapidly. Driven by a vision to drive impactful cell therapy development, the **11th CAR-TCR Summit** is committed to providing in-depth, comprehensive exposure to novel and clinical content across:



\*Data provided by Hanson Wade Conferences as of April 2026

## Breakthrough Unpublished Clinical Data Presentations:



**Proving Durable Autoimmune Responses to Expand Safety, Access & Clinical Impact**



**Developing the UltraCAR-T® Platform to Expand Patient Access & Drive Scalable Manufacturing in Next-Generation Cell Therapy**



**Advancing Autologous Therapies to Enable Durable Solid Tumor Therapy**



**Establishing Durable Impact on Tumors Through Phase 1 Evidence: Bench to Bedside & Back**



**Highlighting Overland Therapeutics' GPRC5D/BCMA Dual CAR-T Clinical Data**

## Highlighting **NEW** Standout Sessions:

Across three days, the **11th CAR-TCR Summit** brings together full-spectrum cell therapy insights, from early development and clinical progression to commercial success and strong patient outcomes. Gain practical takeaways that support smarter pipeline and manufacturing decisions, refined trial designs and stronger long-term program impact to ensure your work is effective and sustainable.



### 3 New Bootcamps

Tuesday, September 15 | 9am - 3pm

Delivering technical content with 3 NEW dedicated high-impact bootcamps, led by industry trailblazers, gain maximum value by taking a deep dive into one critical area.

- **In Vivo:** Unraveling the development, delivery and safety processes which are innovating this next-generation field
- **Automated Manufacturing** and integration to reduce COGs, improve scalability and enable commercially viable cell therapy production
- **Regulatory, Investment & Pharma Partnering;** to align your opportunity to improve collaboration across the full ecosystem of cell therapy to support development and streamline commercial progress



### Investment Insights Panel

Thursday, September 17 | 8.30am

Engage directly with investors to understand their vision for cell therapy across autologous, allogeneic and *in vivo* platforms. Uncover the expectations shaping their investment decisions and sharpen your proposal narrative to align with where capital and partnerships are moving next.



### Patient Perspectives Panel

Thursday, September 17 | 4.15pm

Reconnect with the purpose behind every program. Through powerful first-hand stories, understand lived experiences to refine your therapeutic design, strengthen your focus on accessibility, and ultimately deliver better outcomes for the patients depending on your breakthroughs.



SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS


PRICING &  
REGISTRATION



REGISTER  
NOW

# Your Expert Speakers

## Distinguished Investors:



**Ilya Yasny**  
Partner  
LanceBio Ventures/  
Bioptic



**Patrick Rivers**  
Portfolio Manager  
AMoon Fund



**Randy Berholtz**  
Senior Advisor  
Mesa Verde Venture  
Partners




**Koji Yasuda**  
Principal  
Fast Track Initiative


“The CAR-TCR Summit brings together like-minded teams from around the world to share critical findings and learnings towards continued improvements in patient benefits, and I want to contribute to that endeavor.”

**Mark Exley**, Chief Scientific Officer, **LIFT Biosciences**, 2026 speaker

## Influential C-Suite Leaders:




**Bill Querbes**  
Chief Scientific Officer  
Aera Therapeutics



**Sidharth Kerkar**  
Founder & Chief Executive  
Officer  
Allergene AI



**Luke Pase**  
Chief Technology Officer  
Anocca



**Matthias Will**  
Chief Development Officer  
Autolus Therapeutics



**Robert Keefe**  
Chief Technology Officer  
BlueSphere Bio



**Samik Basu**  
Chief Scientific Officer  
Cabaletta Bio



**Felix Lorenz**  
Chief Executive Officer &  
Chief Scientific Officer  
Captain T Cell



**Ali Soleymannezhad**  
Chief Commercial Officer  
Cellares




**Adrian Kilcoyne**  
Chief Medical Officer  
Cellectis



**Greg Russotti**  
Chief Technology &  
Manufacturing Officer  
Century Therapeutics



**Tom Wickham**  
Chief Scientific Officer  
Gentibio




**Yongke Zhang**  
Chief Scientific Officer  
IASO Biotherapeutics




**Jan Davidson**  
Chief Medical Officer  
Imviva Biotech



**John Byon**  
Chief Medical Officer  
Imugene



**Aaron Edwards**  
Co-Founder & Chief  
Executive Officer  
Kiragen Bio



**Tim Gallagher**  
Chief Operating & Chief  
Business Officer  
PhosphoGam

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW


# Your Expert Speakers

11th Annual  
CAR-TCR Summit

September 15-17, 2026 | Boston, MA



**Shawn He**  
Chief Scientific Officer  
JW Therapeutics



**Ed Zhang**  
Chief Scientific Officer  
Overland  
Pharmaceuticals




**Mark Exley**  
Chief Scientific Officer  
LIFT Biosciences



**Mark Wallet**  
Chief Scientific Officer  
Link Cell Therapies




**Nan Zhang**  
Chief, Cell Therapy  
Manufacturing Section,  
Center for Cellular  
Engineering  
NIH



**Raphaël Ognar**  
President & Chief  
Executive Officer, Co-  
Founder  
NKILT Therapeutics



**Rachel Abbott**  
Chief Executive Officer  
Pan Cancer T



**Daniel Shelly**  
Chief Business  
Development Officer  
PolTREG/Immuthera




**Helen Sabzevari**  
President & Chief  
Executive Officer  
Precigen



**Kanya Rajangam**  
President, Head of  
Research & Development  
& Chief Medical Officer  
Senti Biosciences



**Peggy Sotiropoulou**  
Chief Scientific Officer  
T-Knife Therapeutics



**Leonardo Ferreira**  
Founder & Chief Executive  
Officer  
Torpedo Bio

## Pharma Titans:



**Callum Chapman**  
Head, Global Product  
Quality, Biologics  
AstraZeneca



**Nikhil Mutyal**  
Global Head of Search &  
Evaluation, Respiratory &  
Immunology  
AstraZeneca




**Serena De Vita**  
Vice President, Global  
Franchise Head & Clinical  
Strategy Head, Late  
Development Oncology,  
Cell Therapy, ORD  
AstraZeneca




**Ruth Salmon**  
Vice President, Preclinical  
Sciences  
Bristol Myers Squibb



**Seraphin Kuate**  
Director, Global CMC  
Regulatory, CAR-T Cell  
Therapy  
Bristol Myers Squibb



**Stephan Krause**  
Executive Director,  
Analytical Science &  
Technology, Cell Therapy  
Quality  
Bristol Myers Squibb



**Vaishali Shulka**  
Vice President CGT & API  
Global Expansion  
Eli Lilly & Co.



**Hong Xin**  
Senior Director, Oncology  
Scientific Innovation  
Johnson & Johnson

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

5

[www.car-tcr-summit.com](http://www.car-tcr-summit.com)

Tel: +1 617 455 4188

Email: [info@hansonwade.com](mailto:info@hansonwade.com)

CAR-TCR Summit Series



# Your Expert Speakers

## Pharma Titans:



**Vicki Plaks**

Senior Director, Scientific  
Head of Cell Therapy  
Oncology, Translational  
Research  
Johnson & Johnson



**Lana Shiu**

Global Head, Regulatory  
Affairs  
Kite Pharma




**Jose Caraballo Oramas**

Vice President, Quality  
Kite Pharma



**Chris Crowell**

Global Head,  
Manufacturing  
Kite Pharma




**Balazs Csoka**

Director, Head of Quality  
Control & Analytical  
Science & Technology  
Novartis



**Xiaodong Zhang**

Director, Search &  
Evaluation, Oncology &  
Hematology  
Novartis



**Yu Qian**

Director, Head of  
Analytical Project Leads,  
Cell Therapies  
Novartis



**Russell Goetze**

Director, Analytical  
Development  
Regeneron

## Biotech Visionaries:



**Aaron Cooper**

Vice President, Early  
Discovery  
Arsenal Bio



**Yan Li**

Senior Director, Process  
Development  
Cabaletta Bio



**Enrique Zudaire**

Senior Vice President,  
Translational Sciences &  
Therapeutics Discovery  
Caribou Biosciences



**Justin Skoble**

Vice President, Technical  
Operations  
Caribou Biosciences



NEW COMPANY

**Matthias Bozza**

Director, Head of Strategy  
& R&D  
CPTx



**Pei Wang**

Senior Vice President,  
Clinical Development &  
CMC  
Eureka Therapeutics



NEW COMPANY

**Natalie Shift**

Senior Medical Director  
Fate Therapeutics



**Karine Pozo**

Director, Program  
Management, Cell  
Therapy  
Immatics



**Emad Abdelnaby**

Senior Vice President,  
Head of Commercial  
Legend Biotech



**E-Ching Ong**


Associate Director,  
Process Development  
Lyell Immunopharma



NEW COMPANY

**Michaël Mingueau**

Vice President,  
Immunology  
Sail Biomedicines



**Lyndsey Young**

Executive Director, Quality  
Tr1x Bio



NEW COMPANY

**Luke Russell**


Executive Vice President  
Vyriad



NEW COMPANY


**Chupei Zhang**

Director, Head of MSAT  
Wugen



**Samantha O'Hara**

Director, Product Sciences  
Umoja Biopharma



**Shon Green**

Co-Founder  
Zelig Therapeutics



11th Annual  
**CAR-TCR Summit**

September 15-17, 2026 | Boston, MA

**SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22**

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



**REGISTER  
NOW**

# Your Expert Speakers

11th Annual  
CAR-TCR Summit

September 15-17, 2026 | Boston, MA

## Academic, Regulatory & Cancer Center Leaders:



**Sharon Anderson**  
Vice President, Scientific Affairs  
Alliance for Regenerative Medicine



**Rudolph Hulpas**  
Technical Director, Process Development  
Dana-Farber Cancer Institute



**Xiuyan Wang**  
Director, Biotherapeutics Core Facility  
Memorial Sloan Kettering Cancer Center



**Lavakumar Karyampudi**  
Senior Director, Cell Therapies  
Moffitt Cancer Center



**Bruce Levine**  
Barbara & Edward Netter Professor in Cancer Gene Therapy  
University of Pennsylvania



**Steven Feldman**  
Site Head & Scientific Director, Laboratory for Cell & Gene Medicine  
Stanford GMP Facility



**Kingyin Lee**  
Head of Clinical Trials  
Medicines and Healthcare products Regulatory Agency


## Dynamic Service Providers:




**John Cesarek**  
Senior Director, Automation Engineering  
Cellares



**Jessie H.T. Ni**  
Vice President, Product Development  
BioLegend



**Safia Abdi**  
Lead Research Analyst  
Beacon



**Pierre Springuel**  
Cell & Gene Therapy Specialist  
Sartorius

■ I'm looking forward to connecting with peers to discuss how CAR and TCR innovations are shaping the cell therapy landscape, exchanging perspectives on how clinical development, scalability and commercialization can be optimised to improve patient access and engaging in forward-looking discussions on the next phase of innovation ■

**Serena De Vita**, Vice President, Global Franchise Head & Clinical Strategy Head, Late Development Oncology, Cell Therapy, ORD, **AstraZeneca**, 2026 Speaker

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

# Agenda at a Glance

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

| Pre-Conference Day<br>Tuesday, September 15           |                                                     |                                                        |                                                                 |
|-------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------|
| Cell Therapy<br>Fundamentals<br>Bootcamp              | In Vivo<br>Bootcamp                                 | Automated<br>Manufacturing<br>Bootcamp                 | Regulatory,<br>Investment<br>& Pharma<br>Partnering<br>Bootcamp |
| Decoding T-Cell Biology                               | Advancing <i>in Vivo</i> CAR<br>Design              | Evaluating Automation<br>Strategies                    | Bridging Regulatory<br>Expectations                             |
| Morning Break & Networking                            |                                                     |                                                        |                                                                 |
| Expanding Autoimmune<br>Therapeutic Impact            | Evaluating Vector Delivery<br>Approaches            | Integrating Automation for<br>Manufacturing Excellence | Building Strategic<br>Partnerships Across the<br>Ecosystem      |
| Lunch Break & Networking                              |                                                     |                                                        |                                                                 |
| Optimizing Gene Editing<br>Approaches                 | Defining Safety<br>Assessment & Purity<br>Standards | Expanding QC Automation<br>Opportunities               | Facilitating Face-To- Face<br>Networking                        |
| C-Level Think Tank: Scale Readiness Across Modalities |                                                     |                                                        |                                                                 |

| Conference Day One<br>Wednesday, September 16                                                                        |                                                   |                                                |                                                                      |
|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|------------------------------------------------|----------------------------------------------------------------------|
| Developing CAR & TCR Innovations to Deliver Clinical<br>Impact Across Expanding Indications                          |                                                   |                                                |                                                                      |
| Morning Break & Networking                                                                                           |                                                   |                                                |                                                                      |
| Discovery &<br>Translation                                                                                           | Clinical                                          | Early-Stage<br>Manufacturing                   | Late-Stage<br>Manufacturing                                          |
| Designing CAR & TCR<br>Constructs                                                                                    | Expanding Cell Therapy for<br>Autoimmune Diseases | Leveraging Starting<br>Material Engineering    | Scaling Complex Cell<br>Therapies                                    |
| Lunch Break & Networking                                                                                             |                                                   |                                                |                                                                      |
| Strengthening Cell Therapy<br>Translation                                                                            | Understanding Evolving<br>Global Regulations      | Optimizing Manufacturing &<br>Assay Strategies | Balancing Regulations,<br>Scale & Speed in Cell<br>Therapy Expansion |
| Afternoon Break & Poster Session                                                                                     |                                                   |                                                |                                                                      |
| Advancing T-Cell Therapy Evolution to Enable Durable Solid<br>Tumor Impact & Accelerate Clinical Translation         |                                                   |                                                |                                                                      |
|  CAR-TCR Connect & End of Day One |                                                   |                                                |                                                                      |

| Conference Day Two<br>Thursday, September 17                                            |                                              |                                                         |                                             |
|-----------------------------------------------------------------------------------------|----------------------------------------------|---------------------------------------------------------|---------------------------------------------|
| Securing Funding to Propel Advanced Cell Therapies<br>to Market & Expand Patient Access |                                              |                                                         |                                             |
| Morning Break & Networking                                                              |                                              |                                                         |                                             |
| Discovery &<br>Translation                                                              | Clinical                                     | Early-Stage<br>Manufacturing                            | Late-Stage<br>Manufacturing                 |
| Engineering Cellular<br>Shielding & Gene<br>Knockouts                                   | Delivering Dual CAR-Ts                       | Enhancing CAR &<br>TCR Processing &<br>Characterization | Defining & Refining<br>Specifications       |
| Lunch Break & Networking                                                                |                                              |                                                         |                                             |
| Expanding Innovations<br>Across Cell Therapy                                            | Creating Biomarker-Driven<br>Clinical Trials | Establishing Global<br>Manufacturing                    | Integrating QC<br>Manufacturing Innovations |
| Afternoon Break & Patient Engagement Panel Discussion                                   |                                              |                                                         |                                             |
| Facilitating Clinical Breakthroughs to<br>Accelerate Next-Generation Cell Therapy       |                                              |                                                         |                                             |
| End of the 11th CAR-TCR Summit                                                          |                                              |                                                         |                                             |

CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

# Pre-Conference Day - Tuesday, September 15

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## 8.00 Check-In & Coffee

Welcome to the 11th CAR-TCR Summit. Settle in with refreshments as you spark early conversations with peers focused on the same priorities as you.

| Cell Therapy<br>Fundamentals Bootcamp                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | <i>In Vivo</i> Bootcamp                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Automated Manufacturing<br>Bootcamp                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Regulatory, Investment &<br>Pharma Partnering Bootcamp                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Unpack the biology that drives successful cell therapy development, exploring function and the immunological impact of cell therapies to unearth strategies to enhance persistence, durability and safety and drive future innovation.</p> <p>Whether you're new to cell therapy or looking to refresh your immunology and biology knowledge, build the foundation to shape the future innovations of the field.</p>                                                                                                                                                                                                   | <p>Discover the science, breakthroughs, and challenges driving momentum in <i>in vivo</i> therapies and what's next for this rapidly evolving field.</p> <p>Whether you are actively developing <i>in vivo</i> therapies or exploring the space for the first time, this session is designed to build the insight needed to navigate one of the fastest-growing areas in cell and gene therapy.</p>                                                                                                                                                                                                                                                                                                                     | <p>Explore the latest innovations and practical strategies to automate across development phases, overcoming integration challenges and ensuring consistent outcomes to strengthen commercial viability.</p> <p>For manufacturing experts across all stages of development, looking to the future.</p>                                                                                                                                                                                                                                                                | <p>Step into an immersive experience that clarifies the pharma, biotech and regulatory landscapes and fosters genuine cross-disciplinary collaboration.</p> <p>Amidst evolving regulations, align R&amp;D and GMP early and smooth the regulatory road to clinic. Then shift focus to the commercial drivers that inform a fast move to the clinic as you learn what drives pharma and investor choices, uncover new academic and biotech innovation and connect with promising assets early to unlock stronger partnerships.</p>                                                                                                                                                                                         |
| Decoding Immune Interactions to<br>Maximize CAR-T Performance &<br>Minimize Clinical Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Advancing <i>In Vivo</i> CAR Therapy<br>Design & Strategy to Enable Next-<br>Generation Clinical Success                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Evaluating Automation Strategies<br>to Enable Scalable, High-Quality &<br>Cost-Effective CAR-T Manufacturing                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Bridging Regulatory Expectations to<br>Drive Faster Cell Therapy Success                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <p><b>9.00 Boosting the Efficacy of TCR- &amp; CAR-T Cells Using a Novel TGF-beta SWITCH Receptor</b></p> <ul style="list-style-type: none"><li>SWITCH significantly increases potency of TCR- and CAR-T cells against tumors</li><li>SWITCH receptor targeting TGF-beta, a key defense line of the hostile tumor microenvironment</li><li>SWITCH may be suitable for efficacy-enhancing autologous, allogeneic and <i>in vivo</i> T-cell therapies of solid and hematological tumors</li></ul> <p><b>Felix Lorenz</b>, Chief Executive Officer &amp; Chief Scientific Officer, <b>Captain T Cell</b></p> <p>NEW DATA</p> | <p><b>9.00 Disrupting the Autoimmune Disease Treatment Paradigm - Transient, Potent, &amp; Scalable eRNA-based <i>In Vivo</i> CD19 CAR-T Therapy</b></p> <ul style="list-style-type: none"><li>Leveraging circular eRNA therapeutics and t-LNPs to drive potent, transient <i>in vivo</i> CAR-T cell engineering</li><li>Revolutionizing the autoimmune treatment paradigm by achieving deep B-cell depletion and "immune reboot" with a non-integrative product</li><li>Replacing <i>ex vivo</i> manufacturing with scalable, off-the-shelf IV-dosed therapy, eliminating the need for lymphoablation</li></ul> <p><b>Michaël Mingueneau</b>, Vice President, Immunology, <b>Sail Biomedicines</b></p> <p>NEW DATA</p> | <p><b>9.00 Developing Cell Therapies Leveraging Automated Manufacturing to Reduce COGs while Maintaining Product Quality</b></p> <ul style="list-style-type: none"><li>Discussing strategies to achieve the highest yield with automated manufacturing</li><li>Exploring the stage of development at which to introduce automation</li><li>Showcasing data achieved using automated manufacturing processes in CAR-T and CAR-NK therapies</li></ul> <p><b>Xiuyan Wang</b>, Director, Biotherapeutics Core Facility, <b>Memorial Sloan Kettering Cancer Center</b></p> | <p><b>9.00 Evolving Regulatory Strategy with Cell Therapy Innovation</b></p> <ul style="list-style-type: none"><li>Clarifying CAR-T FDA regulations within existing biologics frameworks to understand current expectations for CMC, preclinical, and clinical development</li><li>Examining FDA regulatory considerations for emerging <i>in vivo</i> and innovative CAR products to highlight where requirements diverge from <i>ex vivo</i> cell therapies</li><li>Adapting development and regulatory strategies to align with evolving FDA guidance, to advance novel cell therapy programs</li></ul> <p><b>Seraphin Kuate</b>, Director, Global CMC Regulatory, CAR-T Cell Therapy, <b>Bristol Myers Squibb</b></p> |

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW



# Pre-Conference Day - Tuesday, September 15

**9.30 Enhancing CAR-T Persistence & Outcomes through IL-2–Driven Optimization & Strategic Combination Therapy**

- Demonstrating how low-dose IL-2 post-infusion improves CAR-T pharmacokinetics, persistence, and clinical durability without additional cell engineering
- Discussing combination-based optimization as a practical pathway to overcoming first-generation allo-CAR-T limitations
- Exploring early clinical direction for integrating BTK inhibition to further enhance efficacy and long-term responses

**John Byon**, Chief Medical Officer, **Imugene**

**10.00 Defining the Depth & Breadth of B-Cell Depletion to Understand the Depth of Therapeutic Success**

- Eliminating progenitor and plasma cells
- Identifying the biomarkers that define B-cell depletion
- Understanding if antibodies retain autoreactivity by tracking antiviral activity

**Jan Davidson**, Chief Medical Officer, **Imviva Biotech**

NEW DATA

**9.30 Panel Discussion: Investigating the Evolution of *In Vivo* Therapies to Accelerate Innovations**

- Discussing the rapid progression of *in vivo* therapies, considering the impact on COGs and patient outcomes
- Highlighting *in vivo* innovations to develop more effective, scalable, and accessible therapies
- Evaluating what's next for *in vivo* therapies to understand anticipated clinical progress, expanding disease indications and projected advancements for strategic planning

**Ruth Salmon**, Vice President, Preclinical Sciences, **Bristol Myers Squibb**

**Luke Russell**, Executive Vice President, **Vyriad**

**Sidharth Kerkar**, Founder & Chief Executive Officer, **Allergene AI**



**9.30 Panel Discussion: Weighing the Pros & Cons of Automated Manufacturing**

- Exploring the adoption of automated manufacturing process to enhance consistency, output and decrease variability
- Examining integration and flexibility challenges in automation to inform realistic implementation strategies
- Analyzing the impact of automation on cost of goods to optimize resource allocation and support sustainable clinical and commercial manufacturing

**Xiuyan Wang**, Director, Biotherapeutics Core Facility, **Memorial Sloan Kettering Cancer Center**

**Stephan Krause**, Executive Director, Analytical Science & Technology, Cell Therapy Quality, **Bristol Myers Squibb**

**Vaishali Shulka**, Vice President, CGT & API Global Expansion, **Eli Lilly & Co.**

**Nan Zhang**, Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering, **NIH**



**9.30 Outlining MHRA Cell Therapy Clinical & Manufacturing Regulations to Ensure Improved Patient Access & Outcomes**

- A window into the MHRA's clinical trial application submission process
- Exploring regulations for new cell therapy innovations
- Discussing the MHRA's decentralized manufacturing process guidelines

**Kingyin Lee**, Head of Clinical Trials, **MHRA**

**10.00 Bridging Regulatory & Commercial Expectations to Restructure the Pathway to Commercialization & Long-Term Follow Ups**

- Evaluating long-term adverse event follow-up trends to determine clinically meaningful safety signals while reducing post-approval burden
- Interpreting evolving regulatory frameworks to enable adaptive decisions that balance patient safety, operational feasibility and commercial sustainability
- Aligning biotech, pharma, academia and patient advocacy stakeholders to support efficient commercialization strategies and evidence-driven long-term study design

**Lana Shiu**, Global Head, Regulatory Affairs, **Kite Pharma**

## 10.30 Morning Break & Networking

Take a moment to pause with tea, coffee and refreshments, continue initial conversations and exchange fresh perspectives ahead of returning to the bootcamp session.

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

CONTENTS

WELCOME

WHAT'S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS

PRICING & REGISTRATION

# Pre-Conference Day - Tuesday, September 15

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <div>Optimizing Approaches to Prevent Downregulation &amp; Improve Durability &amp; Long-Term Cell Therapy Outcomes</div> <div>11.30 Utilizing Targeted Gene Editing to Engineer Durable T-Cell Therapies<ul style="list-style-type: none"><li>Identifying the biological process behind T-cell downregulation</li><li>Identifying and targeting negative regulators of T-cell function to disrupt biological downregulation pathways and preserve potency</li><li>Applying gene editing strategies to intrinsically enhance T-cell durability by preventing functional exhaustion and loss of therapeutic activity</li></ul><div>Enrique Zudaire, Senior Vice President, Translational Sciences &amp; Therapeutics Discovery, Caribou Biosciences</div><div>NEW DATA</div></div> | <div>11.30 Designing <i>In Vivo</i> T-Cell Therapies to Combat Resistance &amp; Enhance Durability in Solid Tumors<ul style="list-style-type: none"><li>Identifying mechanisms of resistance to understand impact <i>in vivo</i> CAR-T durability</li><li>Balancing armored CAR/TCR designs to optimize long-term efficacy while minimizing safety risks</li><li>Evaluating <i>in vivo</i> therapeutic approaches for treating solid tumors in complex tumor microenvironments</li></ul><div>Peggy Sotiropoulou, Chief Scientific Officer, T-Knife Therapeutics</div><div>NEW UNPUBLISHED DATA</div></div> | <div>Orchestrating Automation Integration to Support End-to-End CAR &amp; TCR Manufacturing &amp; QC Excellence</div> <div>11.30 Automating CAR-T Manufacturing: Governance, Validation &amp; Readiness for Commercial Scale<ul style="list-style-type: none"><li>Evaluating where automation delivers the greatest operational value in CAR-T manufacturing processes</li><li>Integrating automated platforms within GMP manufacturing and quality systems while maintaining data integrity and oversight</li><li>Establishing governance and validation strategies to ensure reliability and regulatory readiness as manufacturing scale</li></ul><div>Jose Caraballo Oramas, Vice President, Quality, Kite Pharma</div></div> | <div>Building Strategic Partnerships Across Regulatory Bodies, Pharma, Investors &amp; Academia to Drive Innovation &amp; Growth</div> <div>11.30 Analyzing Acquisition Case Studies to Understand Deal Drivers &amp; Strategic Characteristics<ul style="list-style-type: none"><li>Examining recent acquisitions to identify common characteristics of companies and technologies that attract big pharma interest</li><li>Highlighting deal structures, valuation trends, and strategic priorities to optimize deal readiness and enhance attractiveness for future partnerships or acquisitions</li></ul><div>Safia Abdi, Lead Research Analyst, Beacon</div></div>                                                  |
| <div>12.00 Tailoring CAR-T Cell Therapies for Solid Tumors<ul style="list-style-type: none"><li>Customizing CAR-Ts to upgrade their infiltration and survival</li><li>Building new unexplored solid tumor targets to combat resistant tumors</li><li>Sharing early CAR-T and metastatic treatment</li></ul><div>Leonardo Ferreira, Founder &amp; Chief Executive Officer, Torpedo Bio</div><div>NEW UNPUBLISHED DATA</div></div>                                                                                                                                                                                                                                                                                                                                                  | <div>12.00 Expanding CAR-T Therapies Beyond Cancer &amp; Autoimmune Diseases into Mast Cell Diseases, Allergy &amp; Immunology<ul style="list-style-type: none"><li>Exploring the underlying pathology of allergic diseases</li><li>Designing CAR-T therapies to eliminate mast cells, the cellular cause of allergic reactions</li><li>Defining the unmet need for mast cell targeting CAR-T cells</li></ul><div>Sidharth Kerkar, Founder &amp; Chief Executive Officer, Allergene AI</div><div>NEW DATA</div></div>                                                                                      | <div>12.00 Turning Community Insights into Action<p>Following an inspiring first round of panel insights, and case studies, continue the momentum with expert speakers as they open the floor to deeper, more dynamic discussions. Join this strategy-sharing session to exchange and strengthen ideas, challenge assumptions, and transform insight into actionable value alongside your peers.</p></div>                                                                                                                                                                                                                                                                                                                       | <div>12.00 Panel Discussion: Navigating Regulatory GMP Expectations to De-Risk Development &amp; Enable Market Access<ul style="list-style-type: none"><li>Interpreting updated cell therapy GMP and advanced manufacturing technology expectations to leverage regulatory flexibility without compromising compliance</li><li>Examining how evolving regulatory guidance influences clinical outcomes and commercialization pathways to align manufacturing quality with long-term market success</li></ul><div>Seraphin Kuate, Director, Global CMC Regulatory, CAR-T Cell Therapy, Bristol Myers Squibb</div><div>Sharon Anderson, Vice President, Scientific Affairs, Alliance for Regenerative Medicine</div></div> |

SAVE \$1,000 BY REGISTERING BEFORE FRIDAY, MAY 22

CONTENTS

WELCOME

WHAT'S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS

PRICING & REGISTRATION



REGISTER NOW

# Pre-Conference Day - Tuesday, September 15

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## 12.30 Lunch Break & Networking

Recharge over lunch while reflecting on the morning's insights and uncovering new perspectives with your peers before heading into the afternoon session.

### 1.30 Preventing Tumor Suppression: Multiplex Engineering for Durable CAR-T in GBM

- Contrasting potency-driven approaches with the targeted prevention of multi-axis suppression in solid tumors
- Engineering intrinsic CAR-T resilience through multiplex editing to preempt tumor-mediated downregulation
- Leveraging patient-derived organoids and AI-guided design to accelerate translation and improve predictability

Aaron Edwards, Co-Founder & Chief Executive Officer, Kiragen Bio

NEW DATA

### Evaluating Vector Delivery Approaches to Support Durable Activity & Sustainable *In Vivo* Development

#### 1.30 Non-Viral ssDNA Vector Delivery Strategies to Optimize Persistence & Patient Safety

- *In vivo* immune cell engineering with ssDNA
- Developing strategies to allow long term persistence and gene expression
- Preclinical evidence and scale up

Matthias Bozza, Director, Head of Strategy & R&D, CPTx

NEW DATA

### 1.30 Automating Reagent Management to Streamline Manufacturing & Reduce Costs

- Implementing automated reagent and cytokine management to streamline culture maintenance and reduce errors
- Minimizing media changes and manual handling to improve process efficiency and consistency
- Maintaining high-quality products while reducing cost of goods to support future commercialization

Balazs Csoka, Director, Head of Quality Control & Analytical Science & Technology, Novartis

### Facilitating Face-to-Face Networking Opportunities to Drive innovation & Collaboration

#### 1.30 Panel Discussion: Aligning Pharma Partnership Expectations Across Biotech & Academics to Encourage Successful Collaborations

- Identifying the ideal development stage for engagement to ensure timely and effective collaboration
- Detailing therapies of interest, considering *in vivo* and beyond to identify high-value opportunities
- Discussing collaboration processes beyond initial interest to secure

Hong Xin, Senior Director, Oncology Scientific Innovation, Johnson & Johnson

Nikhil Mutyal, Global Head, Search & Evaluation, Respiratory & Immunology, AstraZeneca

Xiaodong Zhang, Director, Search & Evaluation, Oncology & Hematology, Novartis

### 2.00 Panel Discussion: Selecting Gene Editing Strategies to Prevent Downregulation & Enhance Cell Therapy Outcomes

- Compare knockout, base editing, and prime editing approaches to guide technology selection
- Evaluating alternative strategies such as gene silencing and expression modulation, to reduce biological risk while preserving functional benefit across indications
- Assessing the impact of editing strategies on genomic integrity and patient safety to balance therapeutic enhancement with long-term DNA health and regulatory confidence

### 2.00 Developing High-Quality Lentiviral Vectors to Enhance Reliable Delivery & Reduce Cost

- Examining lentiviral delivery platforms to understand current industry benchmarks and opportunities for innovation
- Optimizing vector design and production strategies to enhance durable CAR expression
- Evaluating scalability and manufacturing readiness of lentiviral vectors to support sustainable *in vivo* clinical and commercial deployment

Luke Russell, Executive Vice President, Vynia

### Expanding Automation Opportunities to Reduce Costs & Improve Data Quality

#### 2.00 Roundtable Discussion: Expanding & Implementing Automation in Analytical & QC Manufacturing Processes

- Facilitating early, open conversations with automation and technology vendors to align process needs, instruments, and materials, reducing integration friction
- Leveraging automation for precise analytical tasks to ensure high assay accuracy
- Reducing operator variability through machine-driven processes to improve data robustness

### 2.00 Pharma & Investor Roundtable Discussions

- Connect directly with leading experts in an interactive roundtable setting, sharing your work and showcasing your assets in focused, face-to-face conversations
- For pharma and investors, engage with senior leaders from pioneering biotech and academics early to uncover opportunities for collaboration
- For biotech, gain actionable insights by hearing what your peers are developing and understand first-hand the direction of pharma and biotech innovation

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS

PRICING & REGISTRATION



REGISTER NOW

# Pre-Conference Day - Tuesday, September 15

|                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p><b>Leonardo Ferreira</b>, Founder &amp; Chief Executive Officer, <b>Torpedo Bio</b></p> <p><b>Aaron Edwards</b>, Co-Founder &amp; Chief Executive Officer, <b>Kiragen Bio</b></p> | <p><b>Defining Safety Assessment &amp; Purity Standards to Support Regulatory-Ready <i>In Vivo</i> Therapies</b></p> <p><b>2.30 Optimizing <i>In Vivo</i> LNP Delivery of CAR mRNAs to Unlock Autoimmune Disease Treatments</b></p> <ul style="list-style-type: none"><li>Optimizing of LNP delivery systems for <i>in vivo</i> CAR-T</li><li>Screening and selecting mRNA cargo</li><li>Assembling preclinical data package to support first in human studies</li></ul> <p><b>Bill Querbes</b>, Chief Scientific Officer, <b>Aera Therapeutics</b></p> | <p><b>Roundtable Discussion Continued</b></p> <div></div> <ul style="list-style-type: none"><li>Leave with new connections, strategic alignment opportunities, and practical knowledge to advance your projects</li></ul> <p><b>Hong Xin</b>, Senior Director, Oncology Scientific Innovation, <b>Johnson &amp; Johnson</b></p> <p><b>Nikhil Mutyal</b>, Global Head, Search &amp; Evaluation, Respiratory &amp; Immunology, <b>AstraZeneca</b></p> <p><b>Patrick Rivers</b>, Portfolio Manager, <b>AMoon Fund</b></p> <p><b>Koji Yasuda</b>, Principal, <b>Fast Track Initiative</b></p> |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.00 End of Bootcamp Day**



**3.30 - 5.00 C-Level Think Tank**

**Scale Readiness Across Modalities**

This invitation-only think tank designed exclusively for C-suite executives offers a rare opportunity to connect with cell therapy leaders across modalities and indications. Exchange perspectives, engage in depth discussions on the most pressing challenges, influence the direction of the field and gain strategic insights that extend beyond the summit.



**Daniel Shelly**, Chief Business Development Officer, **PoITREG/Immuthera**

“I look forward to exchanging ideas with colleagues, sharing my knowledge and expertise in the field, and gaining a deeper understanding of the latest trends in the sector”

**Ilya Yasny**, Partner, **Lance Bio**, 2026 speaker

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



**REGISTER  
NOW**

# Conference Day One - Wednesday, September 16

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22



7.10

**Check-In & Coffee**  
Settle in with morning refreshments while enjoying early, informal access to your peers, collaborators and industry counterparts. Reconnect, align interests from the outset, and identify who you'd like to engage with further across the next two days of the event.

## Developing CAR & TCR Innovations to Deliver Clinical Impact Across Expanding Indications



**Lauren Gollop**  
Senior Program Director

8.10

**Program Directors' Welcome Address**



**Vicki Plaks**  
Senior Director, Scientific  
Head of Cell Therapy  
Oncology, Translational  
Research  
**Johnson & Johnson**

8.15

**Chair's Opening Remarks**

8.20

**Industry Leader's Fireside Chat: Evaluating the CAR & TCR Therapeutic & Commercial Landscape to Propel Advanced Cell Therapy Innovation, Expand Treatment Options & Ensure Positive Commercial Outcomes**

- Highlighting evolving modality innovations and industry shifts to demonstrate how rapid scientific and technological progress is enhancing treatment accessibility and reshaping the cell therapy landscape
- Aligning clinical development, scalability and patient access strategies to accelerate commercialization pathways across advanced cell therapy modalities
- Discussing post-approval reimbursement policies and strategies to ensure long-term commercial success
- Predicting cell therapy evolution through 2026 and beyond to provide strategic and commercial foresight



**Vicki Plaks**  
Senior Director, Scientific Head of Cell  
Therapy Oncology, Translational Research  
**Johnson & Johnson**



**Adrian Kilcoyne**  
Chief Medical Officer  
**Collectis**



**Emad Abdelnaby**  
Senior Vice President,  
Head of Commercial  
**Legend Biotech**



**Serena De Vita**  
Vice President, Global Franchise Head & Clinical Strategy  
Head, Late Development Oncology, Cell Therapy, ORD  
**AstraZeneca**



**Ali Soleymannezhad**  
Chief Commercial Officer  
**Cellares**

8.55

**Delivering Commercial-Ready Cell Therapies at Scale through a Global Network of Smart Factories**

- Case study: successful manufacturing of a clinical-stage CAR-T drug product using the Cellares Cell Shuttle
- Breaking the QC bottleneck with high-throughput, digitally integrated release testing via Cell Q
- Standardizing automation-native facility design across the US, EU, and Japan



**Natalie Shiff**  
Senior Medical Director  
**Fate Therapeutics**

NEW UNPUBLISHED CLINICAL DATA

9.25

**Proving Durable Autoimmune Responses to Expand Safety, Access & Clinical Impact**

- Discussing CAR-T expansion into autoimmunity to enhance future developments
- Showcasing autoimmune clinical data to demonstrate durable responses while improving patient safety and tolerability
- Sharing evolving profiles to illustrate sustained persistence and strengthen confidence in non-conditioning approaches



**Helen Sabzevari**  
President & Chief  
Executive Officer  
**Precigen**

NEW UNPUBLISHED DATA

9.50

**Developing the UltraCAR-T® Platform to Expand Patient Access & Drive Scalable Manufacturing in Next-Generation Cell Therapy**

- Designing multi-component, non-viral UltraCAR-T therapies to overcome biological and delivery limitations
- Reducing cost, time, and complexity to make precision medicine broadly accessible
- Demonstrating early Phase 2 efficacy, safety, and rapid treatment delivery in AML patients, enabled by overnight UltraCAR-T manufacturing



10.15

**Morning Break & Networking**  
Take the opportunity to meet peers, review partners and take part in pre-organized meetings scheduled in the meeting app, then recharge with light refreshments before heading into your preferred track.

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

# Conference Day One - Wednesday, September 16

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <div>Discovery &amp; Translation Track</div> <div>Advance Novel Modalities &amp; Biomarkers with AI, <i>In Vivo</i> Innovation &amp; Translational Relevance</div> <div>This track is tailored for experts in: R&amp;D, Discovery, Translation, Preclinical</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <div>Clinical Track</div> <div>Accelerate Clinical Impact with Smarter Trial Design, Early Apheresis &amp; Patient-Centric Strategies</div> <div>This track is tailored for leaders in: Clinical, Translation, Medical</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | <div>Early-Stage Manufacturing Track</div> <div>Build Phase 1 Processes with Speed, Flexibility &amp; a Clear Path to Commercialization</div> <div>This track is tailored for innovators in: Analytical Development, Process Development, MSAT</div>                                                                                                                                                                                                                                                                                                                                                                                        | <div>Late-Stage Manufacturing Track</div> <div>Scale Up, Reduce Costs &amp; Ensure Quality in Phase 2 &amp; Beyond</div> <div>This track is tailored for specialists in: Manufacturing, CMC, QC, MSAT</div>                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <div>Designing CARs &amp; TCR Constructs to Enhance Treatment Functionality in Solid Tumors</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <div>Expanding Cell Therapies for Autoimmune Diseases to Expand Treatment Opportunities</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | <div>Leveraging Starting Material Engineering &amp; Process Flexibility to Build Robust Manufacturing Foundations</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | <div>Scaling Complex Cell Therapies to Meet Clinical Demand</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <div>11.15 Next-Generation TCR Engineering: Integrating Co-Stimulation &amp; Novel Antigen Targeting to Expand the Reach of T-Cell Therapies</div> <div><ul style="list-style-type: none"><li>Engineering next generation TCR constructs with built in co-stimulatory signaling to deliver dual functionality through a single molecule</li><li>Reducing reliance on additional receptors, knockouts, or complex modifications to improve manufacturability and clinical durability</li><li>Targeting novel solid tumor antigens such as ROPN1 in triple negative breast cancer to address high unmet need and expand the reach of T-cell therapies into new indications</li></ul></div> <div>Rachel Abbott, Chief Executive Officer, Pan Cancer T</div> | <div>11.15 Proving Durable Autoimmune Responses Without Lymphodepletion to Expand Safety, Access &amp; Clinical Impact</div> <div><ul style="list-style-type: none"><li>Showcasing autoimmune clinical data achieved without lymphodepletion to demonstrate durable responses while improving patient safety and tolerability</li><li>Sharing evolving PK profiles to illustrate sustained persistence and strengthen confidence in non-conditioning approaches</li><li>Evaluating safety outcomes and patient engagement benefits to positioning non-conditioning approaches as an accessible and scalable therapeutic strategy</li></ul></div> <div>Samik Basu, Chief Scientific Officer, Cabaletta Bio</div> | <div>11.15 Optimizing Starting Materials to Enable Future Scalable Cell Therapy Production</div> <div><ul style="list-style-type: none"><li>Providing strategies to effectively isolate key starting materials to enhance product yield</li><li>Assessing cell phenotype and fitness to understand how starting material quality impacts manufacturing success</li><li>Applying engineering and process innovations to improve low quality autologous starting material and enable reliable production for clinical supply</li></ul></div> <div>Rudolph Hulpas, Technical Director, Process Development, Dana-Farber Cancer Institute</div> | <div>11.15 Enabling Effective Scale-Up to Deliver Commercialized Complex Cell Therapy Products</div> <div><ul style="list-style-type: none"><li>Working with development, technical leaders to identify scale-up limitations to anticipate risk and guide late-stage process development</li><li>Optimizing engineering, and process integration strategies to reliably build and reproduce complex products at scale</li><li>Defining metrics and success criteria to measure scale-up readiness, ensure product consistency, and support commercial confidence</li></ul></div> <div>Chris Crowell, Global Head, Manufacturing, Kite Pharma</div> |
| <div>11.40 Reserved for Agilent Technologies</div> <div></div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | <div>11.40 Roundtable Discussion: Diversifying Autoimmune Treatments to Enhance Treatment Availability</div> <div><ul style="list-style-type: none"><li>Identify emerging biological targets that unlock new treatment possibilities for complex autoimmune diseases</li><li>Explore multi-target therapeutic approaches that address disease complexity and improve response rates</li><li>Evaluate how to match the right therapeutic modality to the right disease to optimize efficacy, safety, and long-term patient benefit</li></ul></div>                                                                                                                                                               | <div>11.40 Reserved for Fresenius Kabi</div> <div></div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <div>11.40 Minaris Advanced Therapies</div> <div></div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

## CONTENTS

- WELCOME
- WHAT'S NEW
- SPEAKER FACULTY
- AGENDA AT A GLANCE
- PRE-CONFERENCE DAY
- DAY ONE
- DAY TWO
- BECOME A PART OF OUR COMMUNITY
- PARTNERSHIP OPPORTUNITIES
- 2026 PARTNERS
- PRICING & REGISTRATION



REGISTER NOW

# Conference Day One - Wednesday, September 16

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>12.10 Engineering Gated CAR-Ts to Enhance Target Specificity &amp; Combat the Solid Tumor Microenvironment</b> <ul style="list-style-type: none"><li>Designing logic gated CAR-T to overcome on-target off-tumor toxicities in solid tumors</li><li>Utilizing logic <i>in vivo</i> delivery platforms for logic gated CAR-T cells</li><li>Discussing how logic gating enables armoring to enhance potency and overcome suppressive TME</li></ul> <b>Mark Wallet</b> , Chief Scientific Officer, <b>Link Cell Therapies</b> | <b>12.10 Evolving CAR-T Therapies to Shift Beyond Hematological Malignancies</b> <ul style="list-style-type: none"><li>Comparing PK profiles in autoimmune diseases and hematological malignancies to uncover differences in exposure, persistence, and dosing strategies</li><li>Highlighting how endpoints, patient selection, and lymphodepletion approaches differ in lupus and MS</li><li>Exploring clinical safety data to enhance autologous CAR-T expansions beyond oncology</li></ul> <b>Matthias Will</b> , Chief Development Officer, <b>Autolus Therapeutics</b> | <b>12.10 Scaling to Phase 1 – A Biotech &amp; Cancer Center Perspective</b> <ul style="list-style-type: none"><li>Designing small-scale, cost-effective strategies to effectively scale therapies</li><li>Highlighting technologies to secure a high-quality scale to phase 1 clinical trials</li></ul> | <b>12.10 Scaling Cell Therapies to Enable Large Scale Manufacturing &amp; Market Readiness</b> <ul style="list-style-type: none"><li>Leveraging bioreactors to achieve commercial scale</li><li>Comparing with alternative scale-up methods to identify trade-offs in efficiency, control and product quality</li><li>Analyzing cell phenotype post-scale-up to understand the impact of use on product quality</li></ul> <b>Justin Skoble</b> , Vice President, Technical Operations, <b>Caribou Biosciences</b>                                                                                                                                                                                                                                                                                                 |
| <b>12.35 Reserved for Miltenyi Biotec</b> <div><div>Miltenyi Biotec</div></div>                                                                                                                                                                                                                                                                                                                                                              | <b>12.35 Position Reserved for Program Partner</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | <b>12.35 Reserved for Accellix</b> <div></div>                                                                                                                                                                       | <b>12.35 The Future of Cell Therapy Release Testing: Automated QC for High-Throughput, Commercial-Scale Manufacturing</b> <ul style="list-style-type: none"><li>Demonstrating how batchable QC workflows deliver order-of-magnitude increases in release testing throughput and significantly reduce hands-on time, transforming QC into a scalable enabler of commercial CAR-T manufacturing</li><li>Showcasing, as an example, a fully automated flow cytometry assay, from sample barcode scanning and preparation through data capture, analysis, and COA sign-off</li><li>Highlighting a regulatory-ready data strategy that reduces risk, increases consistency, and enables faster, more reliable product release</li></ul> <b>John Cesarek</b> , Senior Director, Automation Engineering, <b>Cellares</b> |

1.05 Lunch Break & Networking  
Private Lunch Hosted by PBS Biotech



Enjoy lunch as you spark new discussions, build relationships that can drive impact throughout the summit.

“I’m excited to reengage across the full cell therapy ecosystem and learn how emerging clinical data, engineering advances, and manufacturing innovations can converge to deliver durable, scalable impact for patients.”  
**Bruce Levine**, Barbara & Edwad Netter Professor in Cancer Gene Therapy, **University of Pennsylvania**

SAVE \$1,000 BY REGISTERING BEFORE FRIDAY, MAY 22

CONTENTS

WELCOME

WHAT'S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS

PRICING & REGISTRATION

REGISTER NOW

# Conference Day One - Wednesday, September 16

| Discovery & Translation Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Clinical Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Early-Stage Manufacturing Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Late-Stage Manufacturing Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Strengthening Cell Therapy Translation through Predictive Models, Safety Insight &amp; Regulatory Alignment</p> <p><b>2.05 Targeting Prostate Cancer: Arsenal Bio's Programmable Circuit T (PCT) Cell Platform &amp; the Development of AB-3028</b></p> <ul style="list-style-type: none"><li>Strengthening CAR-T selectivity with logic gating to safely target solid tumors</li><li>Enhancing CAR-T potency with modular engineering to endure the tumor microenvironment</li><li>Enabling translational readouts to validate cell therapy module function in the clinic</li></ul> <p><b>Aaron Cooper</b>, Vice President, Early Discovery, Arsenal Bio</p> <p>NEW DATA</p>                                                                                                                                                            | <p>Understanding Evolving Regulations Across the Globe to Expand Opportunities for Accelerated Clinical &amp; Commercial Success</p> <p><b>2.05 Charting Regulatory Shifts in CGT: Decisions, Innovation &amp; What's Next</b></p> <ul style="list-style-type: none"><li>Summarizing trends in recent CGT FDA decisions</li><li>Sharing new tools and platform technologies of interest at the FDA</li><li>Diving into FDA trends and future direction</li></ul> <p><b>Sharon Anderson</b>, Vice President, Scientific Affairs, Alliance for Regenerative Medicine</p>                                                                                                                                                                                                                                                                                                                                                                 | <p>Optimizing Manufacturing &amp; Assay Strategies to Enhance Cell Therapy Development &amp; Regulatory Compliance</p> <p><b>2.05 Streamlining Manufacturing Strategies for Complex Allogeneic T-Cell Therapies</b></p> <ul style="list-style-type: none"><li>Incorporating complex allogeneic edits as cell line development to reduce additional editing cycles</li><li>Refining scale up readiness to accelerate timelines while protecting product quality and regulatory compliance</li><li>Aligning with regulators on GMP editing component guidelines</li></ul> <p><b>Greg Russotti</b>, Chief Technology &amp; Manufacturing Officer, Century Therapeutics</p>                                                                                                                                                                                                                                        | <p>Enhancing Cell Therapy Expansion to Balance Scale, Speed &amp; Regulatory Confidence</p> <p><b>2.05 Evaluating Manufacturing to Balance Scientific Rigor &amp; Commercial Scalability</b></p> <ul style="list-style-type: none"><li>Building robust, well-understood processes early to enable reliable and efficient scale-up</li><li>Anticipating technical, cost, and operational constraints that may hinder translation from clinical manufacturing to commercial manufacturing</li><li>Maintaining consistent, adaptable manufacturing and analytical systems from early trials to commercial production</li></ul> <p><b>Lavakumar Karyampudi</b>, Senior Director, Cell Therapies, Moffitt Cancer Center</p> <p>NEW DATA</p> |
| <p><b>2.30 Panel Discussion: Aligning Preclinical Model Selection with Regulatory Expectations to Improve Translation &amp; Approval Confidence</b></p> <ul style="list-style-type: none"><li>Evaluating mouse and non-human primate model translatability to improve clinical predictability</li><li>Comparing model suitability across therapy types to highlight strategic differences that reduce regulatory risk</li><li>Discussing gaps between required regulatory model data and biopharma efficacy needs to align development strategies with translational approval</li></ul> <p><b>Matthias Bozza</b>, Director, Head of Strategy &amp; R&amp;D, CPTx</p> <p><b>Aaron Edwards</b>, Co-Founder &amp; Chief Executive Officer, Kiragen Bio</p>  | <p><b>2.30 Panel Discussion: Highlighting Strategies to Streamline Regulatory Approval Across Regulatory Agencies</b></p> <ul style="list-style-type: none"><li>Detailing the transition process between FDA, EMA and IIT clinical programs to streamline clinical development across borders</li><li>Discussing strategies for incorporating early clinical readouts from international studies to enable faster decision making before US trial initiation</li><li>Evaluating evolving US regulatory comfort with globally generated data to showcase how aligned global development strategies can accelerate innovation while maintaining regulatory rigor</li></ul> <p><b>Pei Wang</b>, Senior Vice President, Clinical Development &amp; CMC, Eureka Therapeutics</p> <p><b>Mark Exley</b>, Chief Scientific Officer, LiFT Biosciences</p>  | <p><b>2.30 USP1043 Compliant GMP-Grade Cell Culture Reagent Supporting Cell-Based Immunotherapy From Bench to Bioprocess</b></p> <ul style="list-style-type: none"><li>Introducing scientists to strategies for scalable pluripotent and/or mesenchymal stem cell culture, with a focus on how GMP-grade reagents that align with USP&lt;1043&gt; can streamline translation into bioprocessing and clinical manufacturing</li><li>Examining key considerations, in addition to potency and performance, in selecting and qualifying ancillary materials to minimize redevelopment timelines and accelerate regulatory readiness</li><li>Understanding how coupling GMP-ready platforms with compliant reagents drives robust innovation and assures a smooth path to recognize its clinical and therefore commercial values</li></ul> <p><b>Jessie Ni</b>, Vice President, Product Development, BioLegend</p> | <p><b>2.30 Reserved for Elevate Bio</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

SAVE \$1,000 BY REGISTERING BEFORE FRIDAY, MAY 22

CONTENTS

WELCOME

WHAT'S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS

PRICING & REGISTRATION

REGISTER NOW

# Conference Day One - Wednesday, September 16

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <div>Panel Discussion continued</div> <div></div>                                                                                                                                                                                                                                                                                                                                           | <div>Panel Discussion continued</div> <div></div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | <div>3.00 Roundtable Discussion: Aligning Assay Strategy with Regulatory Expectations to Streamline Cell Therapy Testing</div> <div><ul style="list-style-type: none"><li>Exploring how to match functional and safety assays with regulatory requirements to ensure robust testing strategies</li><li>Evaluating the use of quality testing for virus replication in cell therapy products despite minimal risk to balance regulatory compliance and assay costs</li><li>Sharing insights on balancing regulatory compliance with scientific rationale to reduce unnecessary testing while maintaining patient safety</li></ul></div> <div>Robert Keefe, Chief Technology Officer, BlueSphere Bio</div> <div>Samantha O'Hara, Director, Product Sciences, Umoja Biopharma</div> | <div>3.00 Panel Discussion: Designing Commercial Manufacturing for Speed or Scale &amp; the Regulatory Trade-Offs</div> <div><ul style="list-style-type: none"><li>Debating whether commercial manufacturing should prioritize commercial scalability from day one or focus on the fastest path into the clinic, and how each choice shapes regulatory strategy</li><li>Examining how early process design and analytical development decisions impact potential CMC approval for commercial studies</li></ul></div> <div>Jose Caraballo Oramas, Vice President, Quality, Kite Pharma</div> <div>Justin Skoble, Vice President, Technical Operations, Caribou Biosciences</div> |
| <div>3.30 IMANs as an Example of Innate Cells' Direct &amp; Indirect Therapeutic Activity</div> <div><ul style="list-style-type: none"><li>Demonstrating innate cell types including IMANs direct therapeutic activity</li><li>Improving and broadening IMAN activity with CARs</li><li>Showing IMANs help CAR-T, CAR-NK and other cell therapies work when they don't</li></ul></div> <div>Mark Exley, Chief Scientific Officer, Lift Biosciences</div> <div>NEW DATA</div> | <div>3.30 Building <i>In Vivo</i> Clinical Success Leveraging the IIT Pathway to Accelerate Global Clinical Development</div> <div><ul style="list-style-type: none"><li>Expand clinical momentum by leveraging the IIT pathway to generate early human data across BCMA <i>in vivo</i> CAR and CD19 CAR-T</li><li>Utilizing clinical insights to inform development strategy</li><li>Sharing practical learnings from IND and IIT discussions to navigate regulatory engagement effectively</li></ul></div> <div>Yongke Zhang, Chief Scientific Officer, IASO Biotherapeutics</div> <div>NEW DATA</div> | <div>3.30 Advancing Cytotoxicity Assays to Strengthen Early CAR-T Development Decisions</div> <div><ul style="list-style-type: none"><li>Leveraging real-time monitoring to enable tumor rechallenge experiments and deeper insight into CAR-T cytotoxic durability and functional exhaustion</li><li>Identifying clinical correlates for preclinical assay results to ensure streamlined Phase I clinical testing</li><li>Applying dynamic assay data to better characterize the cytotoxic profile of final CAR-T products and support confident preclinical-to-Phase I translation</li></ul></div> <div>Russell Goetze, Director, Analytical Development, Regeneron</div>                                                                                                      | <div>3.30 Smart Design &amp; Precision Execution for Late-Stage Allogeneic CAR-T Manufacturing</div> <div><ul style="list-style-type: none"><li>Mitigating risks through strategic approaches in scale-up process tech transfer and manufacturing</li><li>Building and managing partnerships with CDMOs for manufacturing success</li><li>Applying scientific methodologies and phase-appropriate governance across development stages</li></ul></div> <div>Chupei Zhang, Director, Head of MSAT, Wugen</div>                                                                                                                                                                   |

### 3.55 Afternoon Break & Poster Session

Submit a scientific poster to showcase your findings to the industry's market leaders to ignite discussion, test emerging theories and connect for future opportunities. Also take advantage of the opportunity to win the 11th CAR-TCR Summit Poster Prize, selected by our esteemed scientific advisory board. The selected poster winner will have the opportunity to give a 10-minute presentation to the full audience in this dedicated break, providing an opportunity to share key findings, elevate visibility and engage with key experts in this high-impact forum.



SAVE \$1,000 BY REGISTERING BEFORE FRIDAY, MAY 22

CONTENTS

WELCOME

WHAT'S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS

PRICING & REGISTRATION

REGISTER NOW

## Plenary Sessions

### Advancing T-Cell Therapy Evolution to Enable Durable Solid Tumor Impact & Accelerate Clinical Translation

**Lonza**

5.00 Reserved for Lonza



**Pei Wang**  
Senior Vice President, Clinical  
Development & CMC  
**Eureka Therapeutics**  
NEW UNPUBLISHED DATA

5.30 **Advancing Autologous Therapies to Enable Durable Solid Tumor Therapy**

- Engineering T-cells to enhance T-cell fitness and persistence within immunosuppressive tumor microenvironments
- Advancing clinical studies to bridge preclinical promise to patient impact



**Bruce Levine**  
Barbara & Edwad Netter  
Professor in Cancer Gene  
Therapy  
**University of Pennsylvania**  
NEW UNPUBLISHED DATA

5.55 **Establishing Durable Impact on Tumors through Phase 1 Evidence: Bench to Bedside & Back**

- Establishing the path to clinical success to validate solid tumor treatments
- Uncovering clinical data to highlight robust clinical efficacy and durability
- Discussing package considerations to accelerate the path to commercialization



6.20 **CAR-TCR Connect**  
Wrap up day one with a relaxed drinks reception designed to turn great sessions into even better conversations. Reconnect with speakers whose ideas sparked your thinking, swap questions, and insights with peers, and explore topics beyond presentation slides. **Location: The Pavillion**

7.20 **End of Conference Day One**

“I look forward to joining colleagues across the cell therapy community to discuss how advances in manufacturing, automation, and governance can support the reliable and scalable delivery of CAR-T therapies to patients.”

**Jose Caraballo Oramas**, Vice President, Quality Compliance, **Kite Pharma**, 2026 Speaker

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

# Conference Day Two - Thursday, September 17

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22



## 8.00 Check-In & Coffee

Begin the final day of the conference by taking the opportunity to engage with people you missed on day one and deepen initial discussions.

## Securing Funding to Propel Advanced Cell Therapies to Market & Expand Patient Access

## 8.25 Chair’s Opening Remarks

### 8.30 Investors Panel Discussion: Shaping Cell Therapy Funding & Partnerships with Investor Perspectives

- Evaluating funding and investment in cell therapy to uncover future investment interests
- Highlighting key considerations for investment, discussing technology leverage, data packages and more to align priorities and biopharma development strategy
- Facilitating open dialogue to accelerate partnership decisions and investment success in the cell therapy space



**Ilya Yasny**  
Partner  
LanceBio Ventures/Bioptic



**Patrick Rivers**  
Portfolio Manager  
AMoon Fund



**Randy Berholtz**  
Senior Advisor  
Mesa Verde Venture Partners



**Koji Yasuda**  
Principal  
Fast Track Initiative



**Pierre Springuel**  
Cell & Gene Therapy  
Specialist  
Sartorius

## 9.15 Introducing Eveo Cell Therapy Manufacturing Platform: Unlocking the Industrialization of Cell Therapy Production

- Discovering Eveo Cell Therapy Manufacturing Platform’s end-to-end capabilities and built-in readiness for commercial-scale manufacturing and academic scaleout
- Learning how Eveo Platform reduces process complexity and overall costs by enabling flexible, scalable manufacturing through automation and process intensification
- Reviewing Eveo datasets generated by Elevate Bio and the University College London demonstrating process performance and product quality



## 9.45 Why It Matters: Patient Stories Powering CAR-TCR Therapies



## 10.10 Morning Break & Networking

Step into the final day of the event and reconnect as conversations pick up momentum and ideas from day one evolves into deeper discussions.

CONTENTS

WELCOME

WHAT’S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS

PRICING & REGISTRATION



REGISTER  
NOW

# Conference Day Two - Thursday, September 17

| Discovery & Translation Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Clinical Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Early-Stage Manufacturing Track<br>Session Chair: Lonza                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Late-Stage & Manufacturing Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Engineering Cellular Shielding & Gene Knockouts to Enhance Persistence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Delivering Dual CAR-T Innovation to Set Clinical Safety & Efficacy Benchmarks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Enhancing Manufacturing Processes & CAR & TCR Characterization to Measure Potency, Safety & Functionality                                                                                                                                                                                                                                                                                                                                                                                                  | Defining & Refining Manufacturing Processes to Ensure Safe, Flexible & Regulatory-Ready Cell Therapy Development                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <div><b>11.25 Engineering Cellular Shielding to Reduce Allogeneic Rejection</b><ul style="list-style-type: none"><li>Targeting genes that drive immune mediated rejection to protect therapeutic cells</li><li>Applying multi gene knockout approaches to combat complex immune responses and reduce rejection risk</li><li>Evaluating the impact of cellular shielding on long term persistence to demonstrate sustained efficacy and improved patient outcomes</li></ul><div>Tom Wickham, Chief Scientific Officer, GentiBio</div><div>NEW DATA</div></div> | <div><b>11.25 Demonstrating Clinical Success in CD19/CD20 Dual CAR Innovation to Enhance Clinical Impact</b><ul style="list-style-type: none"><li>Detailing the development rationale behind dual CAR design to address resistance challenges and broaden therapeutic applicability</li><li>Showcasing positive IIT clinical trial data for JW Therapeutics' JWCAR201</li><li>Illustrating the potential of dual CAR-T platforms to advance treatment options across oncology and autoimmunity</li></ul><div>Shawn He, Chief Scientific Officer, JW Therapeutics</div></div>                                            | <div><b>11.25 Designing Effective Neoantigen TCR Therapy</b><ul style="list-style-type: none"><li>Matching critical raw materials, characterization, and clinical response</li><li>Balancing production and COGS</li><li>Developing multi-modality approach to treat resistant cancers</li></ul><div>Robert Keefe, Chief Technology Officer, BlueSphere Bio</div><div>NEW DATA</div></div>                                                                                                                 | <div><b>11.25 Defining Phase-Appropriate Control Strategies for Diverse Cell Therapy Products</b><ul style="list-style-type: none"><li>Exploring how phase-appropriate control strategies differ across CAR-T products, to ensure fit-for-purpose development strategies</li><li>Evaluating potency and functional assays tailored to each modality to guide safe and effective transition from first-in-human through later clinical phases</li><li>Discussing the evolution of control strategies from FIH to BLA to establish regulatory confidence</li><li>Considerations for post-license control strategy revisions</li></ul><div>Stephan Krause, Executive Director, Analytical Science &amp; Technology, Cell Therapy Quality, Bristol Myers Squibb</div></div> |
| <div><b>11.50 Enhancing TCR Design to Advance Targeted Delivery &amp; Clinical Impact</b><ul style="list-style-type: none"><li>Optimizing TCR receptors to achieve clinical impact</li><li>Optimizing safe TCRs</li><li>Tailoring gene editing delivery of TCRs</li></ul><div>Luke Pase, Chief Technology Officer, Anocca</div><div>NEW DATA</div></div>                                                                                                                                                                                                      | <div><b>11.50 Biomarkers Associated with Safety &amp; Efficacy of Dual Targeting CAR-T Therapies to Treat Lymphoma</b><ul style="list-style-type: none"><li>Highlighting biomarker data associated with clinical safety, efficacy from Prizlo-cel anti-CD19/CD20 CAR-T therapy</li><li>Showcasing early efficacy results to illustrate how dual targeting improves clinical response</li><li>Utilizing early success to inform next steps towards expanded clinical use</li></ul><div>Vicki Plaks, Senior Director, Scientific Head of Cell Therapy Oncology, Translational Research, Johnson &amp; Johnson</div></div> | <div><b>11.50 Transitioning Between Viral &amp; Non-Viral Platforms to Enhance CAR-T Safety &amp; Durability</b><ul style="list-style-type: none"><li>Transitioning from a viral to non-viral platform for a cell therapy</li><li>Overexpression of genes to enhance CAR-T function using a non-viral strategy for pediatric rare disease</li></ul><div>Steven Feldman, Site Head &amp; Scientific Director, Laboratory for Cell &amp; Gene Medicine, Stanford GMP Facility</div><div>NEW DATA</div></div> | <div><b>11.50 Refining CQAs to Balance Development Flexibility, Product Quality &amp; Patient Safety</b><ul style="list-style-type: none"><li>Optimizing specification ranges to eliminate inefficiencies and ensure consistent outcomes</li><li>Evaluating critical quality attributes (CQAs) and defining release specifications to effectively reflect product quality</li></ul><div>Callum Chapman, Head, Global Product Quality, Biologics, AstraZeneca</div></div>                                                                                                                                                                                                                                                                                                |

SAVE \$1,000 BY REGISTERING BEFORE FRIDAY, MAY 22

CONTENTS

WELCOME

WHAT'S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS

PRICING & REGISTRATION



REGISTER NOW



# Conference Day Two - Thursday, September 17

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <div>12.15 Reserved for Promega Corporation</div> <div></div> <div>12.25 Engineering Next Generation NK-Cell Therapies to Enhance Persistence in Solid Tumors<ul style="list-style-type: none"><li>Showcasing novel NK-cell engineering strategies to enhance serial killing activity and improve functional persistence</li><li>Ensuring better tolerability and improved safety profile</li><li>Presenting preclinical efficacy, safety, and pharmacokinetic data demonstrating enhanced anti-tumor activity and translational potential</li></ul><b>Raphaël G. Ognar</b>, President &amp; Chief Executive Officer, Co-Founder, <b>NKILT Therapeutics</b><div>NEW DATA</div></div> | <div>12.15 Reserved for Innovation Partner</div> <div></div> <div>12.25 Setting the Benchmark for Efficacy &amp; Safety in CAR-T Therapy<ul style="list-style-type: none"><li>Learnings on dual CAR-T design, why targeting CD20xCD22 simultaneously</li><li>Rationale for NHL indication</li><li>Present the eti-cel preliminary data</li></ul><b>Adrian Kilcoyne</b>, Chief Medical Officer, <b>Collectis</b></div>                                                                                                                                                            | <div>12.15 Reserved for Bracco</div> <div></div> <div>12.25 Characterizing CAR Function Across Disease Indications to Enable Clinical Expansion<ul style="list-style-type: none"><li>Measuring CAR targeting and functional activity across diseases to understand indication-specific performance</li><li>Comparing assay approaches assessing binding, functionality and cytotoxicity to ensure cross-indication characterization</li></ul><b>Samantha O'Hara</b>, Director, Product Sciences, <b>Umoja Biopharma</b></div> | <div>12.15 Reserved for Innovation Partner</div> <div></div> <div>12.25 Designing Process Characterization Strategies to Turn Process Knowledge into Predictable Product Success<ul style="list-style-type: none"><li>Unravelling regulatory guidance and process characterization approaches to ensure alignment</li><li>Outlining Lyell's process characterization approach characterization</li><li>Generating actionable data to establish ranges, controls, and a predictable manufacturing process</li></ul><b>E-Ching Ong</b>, Associate Director, Process Development, <b>Lyell Immunopharma</b></div> |
| <div>12.40 Lunch Break &amp; Networking</div> <div>Enjoy Lunch as you build upon the relationships from the summit so far.</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Discovery & Translation Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Clinical Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Early-Stage & Manufacturing Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Late-Stage & Manufacturing Track                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Expanding Innovations Across Cell Types to Expand Next-Generation Development                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Creating Biomarker-Driven Clinical Trials to Optimize Patient Selection, Clinical Outcomes & Trial Timelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Establishing Manufacturing Relationships Early to Accelerate Clinical Timelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Integrating Regulatory, QC & Manufacturing Innovations to Accelerate Clinical & Commercial Cell Therapy Success                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <div>2.10 Innovating Tumor Homing, Scalable Allogeneic Therapy Design to Unlock Cost Effective Cell Therapy Access<ul style="list-style-type: none"><li>Advancing tumor homing technology to improve targeting precision</li><li>Highlighting game-changing manufacturing COGs</li><li>Allogeneic out of the box</li></ul><b>Tim Gallager</b>, Chief Operating &amp; Chief Business Officer, <b>PhosphoGam</b><div>NEW DATA</div></div>                                                                                                                                                                                                                                                                                                                               | <div>2.10 Clinical Activity of IMA203CD8, a PRAME-Directed TCR T-Cell Therapy in Solid Tumors<ul style="list-style-type: none"><li>Targeting of PRAME across tumor types with IMA203CD8 leveraging both CD8+ and CD4+ T cells</li><li>Sharing promising clinical results from a PRAME-directed TCR T-cell therapy including proof-of-concept in ovarian cancer</li><li>Discussing opportunities for tumor-agnostic development across a broad spectrum of PRAME expression levels</li></ul><b>Karine Pozo</b>, Director, Program Management, Cell Therapy, <b>Immatics</b></div> | <div>2.10 Building High-Impact Vendor Partnerships to Accelerate Cell Therapy Execution<ul style="list-style-type: none"><li>Building phase-appropriate quality systems with defined quality indicators to enable early-stage cell therapy development</li><li>Embedding quality indicators into vendor selection and supplier partnerships to protect execution</li><li>Leveraging quality indicators as strategic tools for risk management and operational agility</li></ul><b>Lyndsey Young</b>, Executive Director, Quality, <b>Tr1x Bio</b></div>                                                          | <div>2.10 Defining Potency in CAR-T &amp; Cell Therapies to Align with FDA Expectations<ul style="list-style-type: none"><li>Exploring FDA draft guidance on potency assurance to clarify approaches for demonstrating product functionality and consistency data</li><li>Evaluating matrix and orthogonal potency strategies to ensure robust measurement across diverse patient groups and clinical contexts</li></ul><b>Yu Qian</b>, Director, Head of Analytical Project Leads, Cell Therapies, <b>Novartis</b></div>                                                                                      |

SAVE \$1,000 BY REGISTERING BEFORE FRIDAY, MAY 22

CONTENTS

WELCOME

WHAT'S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS

PRICING & REGISTRATION



REGISTER NOW

# Conference Day Two - Thursday, September 17



September 15-17, 2026 | Boston, MA

## 2.45 Roundtable Discussion: Navigating Regulatory Expectations for Next-Generation Cell Therapies to Accelerate Translation to the Clinic

- Discussing evolving regulatory requirements for CAR-T, TCR, cell therapies to align with compliance standards
- Exploring how regulators are adapting to next-generation modalities, including *in vivo* delivery and manufacturing innovations
- Identifying strategies to design development programs that meet regulatory expectations while accelerating clinical translation

**Ed Zhang**, Co-Founder & Chief Executive Officer, **Overland Pharmaceuticals**

## 2.35 Roundtable Discussion: Utilizing Biomarkers to Guide Patient Selection, Predict Responses & Improve Safety

- Exploring predictive patient and donor biomarkers to determine the cell therapy modalities best suited for individual patients and disease contexts
- Identifying pre-infusion and on-treatment biomarker signals to understand response dynamics and guide clinical decision making
- Evaluating immune fitness and safety related biomarkers to identify patients at risk, anticipate challenges, and enhance therapeutic outcomes

**Kanya Rajangam**, President, Head of Research & Development & Chief Medical Officer, **Senti Biosciences**

## 2.35 Panel Discussion: Designing Early Manufacturing Processes with Long-term Strategic Alignment to Ensure Success in Phase 1 & Beyond

- Establishing strategic manufacturing processes early to ensure phase one clarity, reduced rework and a scalable foundation for future growth
- Identifying optimal opportunities to optimize processes to improve manufacturing and trial outcomes
- Collaborating with flexible manufacturing partners to embed long term strategy from the beginning to support seamless scale up

**Steven Feldman**, Site Head & Scientific Director, Laboratory for Cell & Gene Medicine, **Stanford GMP Facility**

**Greg Russotti**, Chief Technology & Manufacturing Officer, **Century Therapeutics**

## 2.35 Panel Discussion: Accelerating Vein-to-Vein Time through Innovative QC Testing Strategies

- Exploring rapid sterility testing methods, including ATP release assays and NGS-based microbial detection, to reduce traditional 7-day timelines
- Implementing rapid QC testing to accelerate vein-to-vein time without compromising safety and regulatory compliance
- Highlighting emerging technologies demonstrating rapid, reliable testing to support clinical and commercial qc workflows

**Vaishali Shulka**, Vice President, CGT & API Global Expansion, **Eli Lilly & Co.**

**Helen Sabzevari**, President & Chief Executive Officer, **Precigen**

## 3.20 Q-CAR: An *In Vivo* CAR-T Targeting IgE B-Cells as a Treatment for Severe Allergies

- Developing a novel *in vivo* CAR-T approach as a potential cure for severe allergic diseases
- Highlighting the technology, regulatory, and CMC developments that make it possible to envision an *in vivo* CAR-T product for allergy
- Demonstrating preclinical proof of concept, de-risking translation, and defining a successful clinical strategy to advance *in vivo* Q-CAR in allergy

**Shon Green**, Co-Founder, **Zelig Therapeutics**

## 3.20 First In Class Logic Gated Allogeneic CAR Cell Therapy with RMAT Designation Phase 1 Data

- Demonstrating clinical outcomes from phase 1 trials
- Exploring predictive biomarkers to optimize response, safety and trial design in allogeneic therapies
- Showcasing how clinical data enabled regulatory progress and informed pivotal study strategies

**Kanya Rajangam**, President, Head of Research & Development & Chief Medical Officer, **Senti Biosciences**

## 3.20 Roundtable Discussion: Highlighting Differences in US & China Manufacturing Processes to Shift for Scalability

- Comparing US and China manufacturing mindsets to understand the impact of cost-first versus science-first development strategies
- Examining how early manufacturing decisions influence scalability, clinical feasibility, and long-term commercial success
- Examining the role of supplier ecosystems, CDMOs, and local infrastructure in enabling low-cost, high-output cell therapy manufacturing

## 3.20 Applying Proven Manufacturing Strategies to De-Risk Scale-Up & Accelerate Commercial Delivery

- Discussing lessons learned across process optimization, and regulatory alignment to streamline manufacturing and reduce risk
- Leveraging manufacturing strategies to accelerate commercialization and ensure consistent, reliable delivery of therapies

**Yan Li**, Senior Director, Process Development, **Cabaletta Bio**

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

## Plenary Sessions



### 3.45 Afternoon Break & Patient Engagement Panel Discussion

Reconnect with the full audience and enjoy light refreshments. Also taking place in the exhibition hall is the highly anticipated patient engagement panel. Bringing together patients to refocus the event on the shared purpose behind the science and strategy, reinforcing why your conversations and collaborations at the event truly matter to transforming patient lives.



### 4.15 Centering Patient Voices: Experiences, Expectations & Treatment Future

- Spotlighting patient stories to understand the impact of CAR and TCR therapies on patient lives
- Aligning clinical expectations with patient experiences to ensure development strategies prioritize meaningful benefit from discovery through delivery
- Exploring patient and clinician perspectives on *in vivo* therapies to understand acceptance, concerns, and expectations around emerging treatment approaches

Location: The Galleria

## Facilitating Clinical Breakthroughs to Accelerate Next-Generation Cell Therapy



**Ed Zhang**  
Co-Founder & Chief Executive Officer  
Overland Pharmaceuticals  
NEW UNPUBLISHED DATA

### 5.00 Highlighting Overland Therapeutics' GPRC5D/BCMA Dual CAR-T Clinical Data

- Demonstrating early-stage clinical safety and efficacy performance to advance dual targeted cell therapies
- Discussing next steps for dual CAR-T innovation for complex diseases



**Safia Abdi**  
Lead Research Analyst  
Beacon

### 5.25 CAR & TCR Therapies: A Landscape Review

- Reviewing the cell therapy landscape
- Exploring the *in vivo*, autoimmune and expanded target boom to understand the future direction of the space
- Harnessing the insights of Beacon to accelerate the development of your own cell therapy pipeline

### 5.55 Chair's Closing Remarks

### 6.00 End of the 11th CAR-TCR Summit

■ The summit successfully navigated the full spectrum of CAR and TCR therapy challenges, from early-stage innovation to commercialization strategies, while providing invaluable insights from academic leaders and facilitating meaningful networking ■

**Peggy Sotiropoulou**, Chief Scientific Officer, **T-Knife Therapeutics**, 2026 Speaker

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

# More than a Meeting

Unmatched quality collaboration opportunities are around every corner with built-in networking sessions:



Personalize your schedule to maximize strategic value for your program, pipeline or investment interests by scheduling **1:1 meetings** with your priority contacts.



Continue conversations from the day, meet new faces and turn informal connections into new relationships and future opportunities at the **CAR-TCR Connect drinks reception**



Join the **poster session** to uncover cutting-edge innovation and early-stage research, and spark new ideas and collaborations. Showcase your work to a curated community of experts, where the winning poster (selected by our scientific advisory board), will earn the opportunity to present to the full audience.



Utilize the **badge swap app** to ensure your new connections continue beyond the meeting and long-term partnerships are formed. Last year, over 3,100 badge swaps were made!



Engage in **scientific, manufacturing and partnership roundtables** leveraging dedicated networking time with pharma, VC and biotech leaders to explore challenges, share innovation and gain direct insight into collaborative opportunities.

## Previously Attending Companies

### Commercialized Companies



### Pharma



### TCR-T



### In Vivo



### Academics & Cancer Centers



### Solid Tumor Focus



### Autoimmune Focus



SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

# Showcase Your Solutions



## Demonstrate Your Value Where It Matters Most

Showcase how your solutions integrate seamlessly with pharma, biotech and academic pioneers at each stage of CAR and TCR development, demonstrating a tangible impact on the construct design, scalable manufacturing and clinical translation outcomes they prioritize. Position your organization at the center of high-value discussions with market-shaping decision makers that accelerate partnerships and unlock long-term commercial opportunity.



## Turn Emerging Innovations into Growth Opportunities

Unlock direct, early access to uniquely identified, high-impact innovations across the cell therapy value chain, from next generation receptor design and novel vectors to manufacturing strategies to reduce vein-to-vein time. Understand the evolving needs of biopharma forerunners, anticipate market shifts and evolve your service to solve tomorrow's challenges, outpacing your competitors and capturing new revenue and growth opportunities.



## Secure Flagship Status in the Cell Therapy Field

Position your brand alongside the most respected voices in cell therapy, from commercialized hematological malignancy front-runners to emerging in vivo, third-generation and autoimmunity focused developers, demonstrating your consistent support amid ever-changing dynamics to strengthen your reputation with the leaders who set the pace. Keep your organization front-of-mind in the next industry's next defining conversations and deals.




**Kieran Crewe**  
Partnerships Manager  
Telephone: +1 617 455 4188  
Email: [sponsor@hansonwade.com](mailto:sponsor@hansonwade.com)




**Charlotte Hodgson**  
Partnerships Manager  
Telephone: +1 617 455 4188  
Email: [sponsor@hansonwade.com](mailto:sponsor@hansonwade.com)

## COMPANY TYPE:



## SENIORITY:



\*Statistics taken from the 10<sup>th</sup> CAR-TCR Summit

## Partnership Opportunities Include:



**Data-driven or case study led presentations** to position yourself as an experienced, technical leader



**Partner pods** (3x3 booths) to expand your brand visibility



**Chair important conversations** to shape forward-thinking discussions



**Exhibition booths** to enhance brand awareness and showcase your product to prospective customers



**Exclusive access to the full delegate list** to plan ahead and make every conversation count



**Hosted lunches, drinks reception, and dinners** to facilitate more connections with your target audience



**Align your brand with CAR and TCR therapy** to build a brand synonymous with driving the space forward

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

# 2026 Partners

## Lead Partner



Cellares is the world's first Integrated Development and Manufacturing Organization (IDMO), pioneering the industrialization of cell therapy. Our automated platforms and global footprint enable biotech and pharma companies to achieve clinical outcomes faster, with greater reliability, and at lower cost. Together with our partners, we are accelerating patient access to life-saving therapies.

[www.cellares.com](http://www.cellares.com)

## Expertise Partners

# Lonza

Lonza is one of the world's largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. Working across five continents, our global team of around 18,500 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. We support our customers in bringing life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.

[www.lonza.com](http://www.lonza.com)

# SARTORIUS

Sartorius is a leading global partner of the biopharmaceutical industry dedicated to enabling cell and gene therapy developers to manufacture and commercialize their advanced therapy medicinal products (ATMPs). Over the last decade the company has expanded its legacy portfolio of single-use bioprocessing solutions through the acquisition of complementary advanced therapy consumables, services, and technologies—from plasmid engineering and manufacturing to cell culture media, reagents and monolithic chromatography. Sartorius' advanced therapy solutions are designed to overcome current ATMP production challenges by enhancing productivity, improving process economics, and supporting safe and regulatory compliant manufacturing. Sartorius products are currently used in approved cell and gene therapies and actively support clinical pipelines worldwide. The company's continued investment in innovative solutions demonstrates their commitment to advancing the field and making access to these life-saving treatments a reality.

[www.sartorius.com](http://www.sartorius.com)

SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

# 2026 Partners

## Program Partners



## Hosting Partner



## Innovation Partner



## Exhibition Partners



## Event Partner



SAVE \$1,000 BY  
REGISTERING  
BEFORE  
FRIDAY,  
MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER  
FACULTY

AGENDA AT A  
GLANCE

PRE-CONFERENCE  
DAY

DAY ONE

DAY TWO

BECOME A  
PART OF OUR  
COMMUNITY

PARTNERSHIP  
OPPORTUNITIES

2026  
PARTNERS

PRICING &  
REGISTRATION



REGISTER  
NOW

# Ready to Register?

## Team Discounts

- 3 Passes - 15% Discount
- 4+ Passes - 20% Discount

Bring the full team to maximize learning and connection opportunities with 200+ attending companies across the cell therapy ecosystem and actionable insights across 4 simultaneous tracks.

Group discounts cannot be used in conjunction with any other discounts. Group discounts can still be applied to early bird savings. For more information on group rates and eligibility criteria, please email [info@hansonwade.com](mailto:info@hansonwade.com) or visit the website. Full T&Cs apply.

**1 Be first to access unpublished clinical data**, emerging innovations, advanced manufacturing strategies, and high-impact collaboration insights. Equip your team with insights across the full development lifecycle to unify strategy, strengthen your pipeline, and accelerate from bench side breakthroughs to commercial success.

**2 Build multidimensional relationships** with a highly targeted forum of C-suite and senior leaders across pharma, biotech, academia, and investment, unlocking an unmatched depth of conversation to solve shared challenges, exchange high-value ideas, and unlock meaningful collaboration.

**3 Harness world-class scientific manufacturing and commercial leadership** as leading KOLs and industry trailblazers deliver exclusive actionable insights that de-risk development and drive measurable progress to fast track your clinical delivery while strengthening commercial longevity.

| Drug Developer Pricing*                                                                   | Register By Friday, May 22    | On The Door |
|-------------------------------------------------------------------------------------------|-------------------------------|-------------|
| Conference + (Fundamentals Day OR <i>In Vivo</i> Day OR Automation Day OR Partnering Day) | \$3,397 <b>(Save \$1,000)</b> | \$4,397     |
| Conference Only                                                                           | \$2,599 <b>(Save \$500)</b>   | \$3,099     |
| Academic & Small Scale Biotech Pricing**                                                  | Register By Friday, May 22    | On The Door |
| Conference + (Fundamentals Day OR <i>In Vivo</i> Day OR Automation Day OR Partnering Day) | \$2,797 <b>(Save \$1,000)</b> | \$3,797     |
| Conference Only                                                                           | \$2,199 <b>(Save \$500)</b>   | \$2,699     |
| Service Provider Pricing                                                                  | Register By Friday, May 22    | On The Door |
| Conference + (Fundamentals Day OR <i>In Vivo</i> Day OR Automation Day OR Partnering Day) | \$5,677 <b>(Save \$900)</b>   | \$6,577     |
| Conference Only                                                                           | \$4,779 <b>(Save \$500)</b>   | \$5,279     |

\*Must be from a biotech or pharma company that is currently and publicly developing an in-house cell therapy to be eligible for this price

\*\*Must be from a biotech company with less than 50 full-time employees that is currently and publicly developing an in-house cell therapy, or be a full time academic to be eligible for this price

## 3 Easy Ways To Book



[www.car-tcr-summit.com/register/](http://www.car-tcr-summit.com/register/)



Email: [register@hansonwade.com](mailto:register@hansonwade.com)



Tel: +1 617 455 4188

## VENUE

### The Westin Boston Seaport District

425 Summer St, Boston, MA 02210

[www.marriott.com/en-us/hotels/bosow-the-westin-boston-seaport-district/overview/?clickref=1100IAAizwTj&aff=MARWW&affname=1011110&co=WW&nt=PH](http://www.marriott.com/en-us/hotels/bosow-the-westin-boston-seaport-district/overview/?clickref=1100IAAizwTj&aff=MARWW&affname=1011110&co=WW&nt=PH)

New Venue

### TERMS & CONDITIONS

**Full payment is due on registration. Cancellation and Substitution Policy:** Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

**Changes to Conference & Agenda:** Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Ltd is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

**Data Protection:** The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade Conferences Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

29

[www.car-tcr-summit.com](http://www.car-tcr-summit.com)

Tel: +1 617 455 4188

Email: [info@hansonwade.com](mailto:info@hansonwade.com)



CAR-TCR Summit Series



REGISTER NOW

SAVE \$1,000 BY REGISTERING BEFORE FRIDAY, MAY 22

## CONTENTS

WELCOME

WHAT'S NEW

SPEAKER FACULTY

AGENDA AT A GLANCE

PRE-CONFERENCE DAY

DAY ONE

DAY TWO

BECOME A PART OF OUR COMMUNITY

PARTNERSHIP OPPORTUNITIES

2026 PARTNERS

PRICING & REGISTRATION